Amgen Biosimilars Game On: Filing Chases AbbVie's Humira
This article was originally published in Scrip
Executive Summary
After being the company whose products have been in hot pursuit by makers of biosimilars, Amgen Inc. is seeking to market one of its own, ABP 501, a biosimilar version of AbbVie Inc.'s Humira (adalimumab) – aiming to take a bite out of the nearly $13bn in annual sales the latter firm brings in for its tumor necrosis factor (TNF) blocker.